mRNA 1172
Alternative Names: mRNA-1172; Respiratory syncytial virus (RSV) vaccine - Merck-&-Co/Moderna-Therapeutics; RSV vaccine - Moderna Therapeutics; V-172Latest Information Update: 28 Sep 2022
At a glance
- Originator Moderna Therapeutics
- Developer Merck & Co; Moderna Therapeutics
- Class Respiratory syncytial virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(Prevention) in USA (Parenteral)
- 08 Oct 2020 Moderna regains all rights of mRNA 1172 from Merck & Co
- 08 Aug 2019 Phase-I clinical trials in Respiratory syncytial virus infections (Prevention) in USA (Parenteral)